SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Enanta Pharmaceuticals (ENTA)

ENTA RSS Feed
Add ENTA Price Alert      Hide Sticky   Hide Intro
Moderator: TREND1, DewDiligence
Search This Board: 
Last Post: 11/14/2017 2:19:31 PM - Followers: 63 - Board type: Free - Posts Today: 0
SureTrader
Interactive Brokers Advertisement
ENTA
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ENTA News: Amended Statement of Beneficial Ownership (3/a) 11/14/2017 05:49:48 PM
ENTA News: Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Fou... 11/13/2017 07:30:00 AM
ENTA News: Enanta Pharmaceuticals Announces Positive Phase 1 a/b Clinical Results for its Lead FXR Agonist, EDP-305 10/23/2017 07:30:00 AM
ENTA News: Enanta Pharmaceuticals to Present New Preclinical Data on EDP-305, an FXR Agonist for NASH and PBC, at The Liver Meeting® 2017 10/20/2017 08:02:00 AM
ENTA News: Enanta Announces Data to be Presented on AbbVie’s MAVYRET™ (glecaprevir/pibrentasvir) at The Liver Meeting® 2017 10/11/2017 03:03:00 PM
PostSubject
#1541  Sticky Note ENTA DAY TREND1 11/14/17 02:14:41 PM
#1483  Sticky Note FDA approves ABBV/ENTA’s Mavyret: #msg-133548596. DewDiligence 08/03/17 03:24:43 PM
#1544   Float = 16.02M TREND1 11/14/17 02:19:31 PM
#1543   Earnings Per Share (EPS) = 1.14 TREND1 11/14/17 02:17:11 PM
#1542   Profit/Loss = 21.67M TREND1 11/14/17 02:16:26 PM
#1541   ENTA DAY TREND1 11/14/17 02:14:41 PM
#1540   Mavyret US scripts—week ending 11/3/17: #msg-136101015. DewDiligence 11/10/17 09:42:30 AM
#1539   No news that I'm aware of. DewDiligence 11/07/17 03:10:46 PM
#1538   Yikes! What happened here today? JK2016 11/07/17 03:02:05 PM
#1537   Mavyret US scripts—week ending 10/27/17: #msg-135920382. DewDiligence 11/03/17 10:02:09 AM
#1536   No—still searching for an explanation. DewDiligence 11/02/17 11:33:23 AM
#1535   Dew did you ever come up with an Bickema 11/02/17 11:29:46 AM
#1534   ABBV reduces ENTA equity stake slightly: #msg-135761339. DewDiligence 10/27/17 05:25:47 PM
#1533   Mavyret will have peak annual sales of “multi-billions,” DewDiligence 10/27/17 09:33:14 AM
#1532   Mavyret 3Q17 sales (partial quarter) ~$100M: #msg-135740870. DewDiligence 10/27/17 09:28:25 AM
#1531   The EDP-305 phase-1/1b data are everything investors could DewDiligence 10/23/17 12:47:58 PM
#1530   ENTA reports phase-1/1b data for EDP-305: DewDiligence 10/23/17 11:47:47 AM
#1529   Dew, any thoughts on the data? Or rajaram46 10/23/17 11:40:55 AM
#1528   Caution: My 40% number represents patient share, not DewDiligence 10/20/17 12:17:52 PM
#1527   I saw it in an article recently but Bickema 10/20/17 12:17:22 PM
#1526   Thanks. Where did you find that chart? DewDiligence 10/20/17 12:16:25 PM
#1525   Judging by this Bloomberg chart, 'analyst' aren't expecting Bickema 10/20/17 12:13:36 PM
#1524   AASLD full-text presentations should be available at: DewDiligence 10/20/17 12:12:27 PM
#1523   So is the data accessible? Or will rajaram46 10/20/17 12:06:02 PM
#1522   ENTA’s EDP-305 presentations at AASLD: DewDiligence 10/20/17 11:56:41 AM
#1521   Yes, I think it does. DewDiligence 10/20/17 11:46:06 AM
#1520   Doesn't that imply significant upside to ENTA, on rajaram46 10/20/17 11:44:18 AM
#1519   Mavyret should be able to get a 40% DewDiligence 10/20/17 11:23:21 AM
#1518   Mavyret scripts for week ending 10/13/17: #msg-135560245. DewDiligence 10/20/17 11:21:58 AM
#1517   What's your low estimate guess on where market nowlurking 10/20/17 10:40:58 AM
#1516   (EDIT)You might be interested in AASLD abstract #205 willyw 10/10/17 11:17:37 AM
#1515   Mavyret scripts for week ending 9/29/17: #msg-135250104. DewDiligence 10/09/17 11:57:57 AM
#1514   FDA's Approval Of A Cheaper Drug For Hepatitis willyw 10/04/17 08:09:59 AM
#1513   Mavyret scripts for week ending 9/22/17: #msg-135002682. DewDiligence 09/29/17 10:15:55 AM
#1512   That's not Barron's per se—it's a sell-side note DewDiligence 09/28/17 02:53:16 PM
#1511   http://www.barrons.com/articles/gileads-china-entrance-looks-crowded-1506532587 willyw 09/28/17 02:28:15 PM
#1509   Many investors think that HCV is tapped out. DewDiligence 09/28/17 12:05:12 PM
#1508   The SA piece is assuredly wrong about Viekira DewDiligence 09/28/17 12:03:53 PM
#1507   Maviret in China? willyw 09/28/17 12:01:14 PM
#1506   ENTA’s AASLD presentations for EDP-305 (NASH/PBC): DewDiligence 09/27/17 04:24:00 PM
#1505   Japan approves Maviret, triggering $15M milestone payment: #msg-134935488. DewDiligence 09/27/17 09:44:02 AM
#1504   Mavyret scripts for week ending 9/18/17: #msg-134887306. DewDiligence 09/25/17 03:14:49 PM
#1503   New slide set from CF presentation today: DewDiligence 09/25/17 09:38:10 AM
#1502   Highest intraday and closing prices since Aug2015 (eom). DewDiligence 09/15/17 04:21:28 PM
#1501   Mavyret scripts for week ending 9/8/17 (from IMS)… DewDiligence 09/15/17 10:10:30 AM
#1500   Yes, I erroneously switched the numbers—will repost. Thanks DewDiligence 09/15/17 10:08:36 AM
#1499   Shouldn't Total be bigger than new? DaveAu 09/15/17 10:04:33 AM
#1497   RBC Capital initiates coverage on Enanta Pharmaceuticals (NASDAQ: Bickema 09/15/17 08:37:05 AM
#1496   Thank you Dew. Bickema 09/14/17 10:45:33 AM
#1495   Mavyret scripts for the week ending 9/1/17 were DewDiligence 09/14/17 10:42:46 AM
#1494   Dew or Anyone else seen any new script Bickema 09/14/17 10:39:36 AM
#1493   ENTA adds director—BoD size increased to 7: DewDiligence 09/13/17 08:58:07 AM
PostSubject